Arbutus Biopharma Logo
Arbutus to Report Second Quarter 2019 Financial Results
29 juil. 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., July 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it...
Arbutus Biopharma Logo
Arbutus Announces Preliminary Phase 1a/1b Clinical Trial Results for AB-506, an Oral Capsid Inhibitor in Development for People with Chronic Hepatitis B
15 juil. 2019 16h05 HE | Arbutus Biopharma Corporation
Results demonstrate that AB-506 is a potent capsid inhibitor Phase 1a/1b clinical trial to continue with the enrollment of further cohorts Conference call and webcast scheduled today at 4:45 pm ET ...
Arbutus Biopharma Logo
Arbutus Sells Part of its ONPATTRO™ (patisiran) Royalty Interest to OMERS
02 juil. 2019 16h01 HE | Arbutus Biopharma Corporation
 - Arbutus to receive $20 million in gross proceeds before advisory fees while retaining significant downstream economics  - Runway extended with non-dilutive capital WARMINSTER, Pa., July 02,...
Arbutus Biopharma Logo
Arbutus receives regulatory clearance to initiate Phase 1a/1b Clinical Trial of AB-729
20 juin 2019 07h30 HE | Arbutus Biopharma Corporation
- AB-729 is a subcutaneously-administered RNAi agent targeting HBV replication and HBsAg antigen production - Supports corporate objective to combine AB-729 with AB-506, Arbutus’ proprietary oral...
Arbutus Biopharma Logo
Arbutus Appoints William Collier as Next President & CEO and Announces Retirement of Current President & CEO, Mark J. Murray Ph.D.
17 juin 2019 07h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., June 17, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the...
Arbutus Biopharma Logo
Arbutus to Participate at JMP Securities Life Sciences Conference
13 juin 2019 08h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., June 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Biopharma Logo
Arbutus to Present at Upcoming May 2019 Conferences
13 mai 2019 08h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., May 13, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr....
Arbutus Biopharma Logo
Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update
06 mai 2019 16h01 HE | Arbutus Biopharma Corporation
Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019 Conference Call and...
Arbutus Biopharma Logo
Arbutus to Report First Quarter 2019 Financial Results
29 avr. 2019 08h30 HE | Arbutus Biopharma Corporation
WARMINSTER, Pa., April 29, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it...
Arbutus Biopharma Logo
Arbutus Reports Fourth Quarter and Year-end 2018 Financial Results and Describes Recent Clinical Accomplishments and Key 2019 Objectives
07 mars 2019 16h01 HE | Arbutus Biopharma Corporation
- Clinical trial results expected for AB-506, a potent capsid inhibitor, and AB-729, a subcutaneously administered RNAi agent targeting HBsAg - Ongoing analyses of AB-452, a novel orally-available...